ATP1A3 (C-terminal) Polyclonal antibody

ATP1A3 (C-terminal) Polyclonal Antibody for WB, IF, IHC, ELISA

Host / Isotype

Rabbit / IgG


human, mouse, rat





Cat no : 10868-1-AP


ATP1A3, ATP1A3 (C-terminal), DYT12, RDP, Sodium pump subunit alpha 3

Tested Applications

Positive WB detected inC2C12 cell, mouse brain tissue, C2C12 cells
Positive IHC detected inhuman prostate cancer tissue, mouse brain tissue, mouse skeletal muscle tissue, human cerebellum tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inmouse brain tissue

Recommended dilution

Western Blot (WB)WB : 1:500-1:3000
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)IF : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

10868-1-AP targets ATP1A3 (C-terminal) in WB, IF, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen ATP1A3 (C-terminal) fusion protein Ag1313
Full Name ATPase, Na+/K+ transporting, alpha 3 polypeptide
Calculated Molecular Weight 113 kDa
Observed Molecular Weight 100-113 kDa
GenBank Accession NumberBC015566
Gene Symbol ATP1A3
Gene ID (NCBI) 478
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

ATP1A3 participates in the catalyticing hydrolysis of ATP and the exchanging of sodium and potassium ions across plasma membrane. The catalyticing activity mode is ATP + H2O + Na+(In) + K+(Out) = ADP + phosphate + Na+(Out) + K+(In). It has been published that the neurologic disorders rapid-onset dystonia-parkionsonism (RDP), alternating hemiplegia of childhood (ACH) and CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss) are all related with the mutation of ATP1A3. There are other reports suggest that early life epilepsy and episodic apnea revealing are potentially associated with the mutation of ATP1A3 as a result of impairment of Na+/K+ homeostasis. This antibody is generated against the C-terminal region (665-1013aa) of ATP1A3 and detects the band around 100-113 kDa in SDS-PAGE.(PMID: 30097153, 20301294, 29922587)


Product Specific Protocols
WB protocol for ATP1A3 (C-terminal) antibody 10868-1-APDownload protocol
IHC protocol for ATP1A3 (C-terminal) antibody 10868-1-APDownload protocol
IF protocol for ATP1A3 (C-terminal) antibody 10868-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Front Oncol

Elevated Sodium Pump α3 Subunit Expression Promotes Colorectal Liver Metastasis via the p53-PTEN/IGFBP3-AKT-mTOR Axis.

Authors - Di Wu

Cancer Cell Int

Comprehensive analysis of the expression of sodium/potassium-ATPase α subunits and prognosis of ovarian serous cystadenocarcinoma.

Authors - Wei Huang

Life Sci

Identification of a robust scoring system based on metabolic genes followed by in-depth validation of ATP1A3 in glioma

Authors - Qiankun Ji